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ABSTRACT 
PURPOSE: To evaluate the one-year efficacy and safety of photodynamic therapy (PDT) 
combined with intravitreal injections of ranibizumab for polypoidal choroidal vasculopathy 
(PCV). 
DESIGN: Retrospective chart review. 
METHODS: We retrospectively reviewed the medical records of 63 consecutive patients 
(66 eyes) with subfoveal PCV who were treated with PDT combined with intravitreal 
injections of ranibizumab. Of the 66 eyes, 29 had no history of treatment for PCV, 10 had 
been treated previously with only intravitreal injections of anti-vascular endothelial growth 
factor (VEGF) agents, and 27 had been treated previously with PDT. All eyes had a 
minimal follow-up of 12 months. 
RESULTS: The combined therapy reduced substantially the exudative change 
immediately after initiation of treatment. In treatment-naïve eyes, mean VA before 
treatment (0.47 ± 0.37 in logMAR) improved to 0.32 ± 0.30 (P < .01) at three months and 
to 0.29 ± 0.29 (P < .01) at 12 months. Polypoidal lesions were reduced in all eyes and 
disappeared completely in 79.1% of cases. In eyes treated previously with only 
anti-VEGF therapy, some visual improvement was achieved, but in eyes treated 
previously with PDT, mean VA (0.61 ± 0.45) deteriorated to 0.68 ± 0.52 at 12 months.   
Abstract (MUST be submitted as a separate file)
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Of all 66 eyes, 5 showed extensive postoperative subretinal hemorrhage, 2 of which 
developed a vitreous hemorrhage and underwent pars plana vitrectomy.  
CONCLUSIONS: PDT combined with ranibizumab led to significant visual recovery in 
treatment-naïve eyes with PCV, but not in eyes with PCV that had recurred after previous 
PDT. PDT in combination with ranibizumab still has a risk of the postoperative 
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Today, intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are 
a standard treatment for exudative age-related macular degeneration (AMD).1, 2 As a 
unique form of choroidal neovascularization (CNV),3-5 polypoidal choroidal vasculopathy 
(PCV) is characterized by a branching vascular network that terminates in polypoidal 
lesions.6-9 Similar to AMD,10 recent findings of high concentrations of VEGF in aqueous 
humor11 and high expression of VEGF in histologic specimens of PCV12 have suggested 
that VFGF is involved also in the pathogenesis of PCV. In contrast to AMD, however, it 
has been reported that the treatment effects of anti-VEGF agents on the vascular lesions 
associated with PCV are limited.13-24 In a recent report of PCV by Hikichi and 
associates,25 although exudative changes regressed with three monthly injections of 
ranibizumab, with concomitant improvement of visual acuity (VA), complete 
disappearance of the polypoidal lesions was achieved in only 26% of eyes. 
     A number of studies have shown encouraging results of photodynamic therapy 
(PDT) on PCV.26-30 In a report by Chan and associates,27 PDT led to complete regression 
of the polypoidal lesion in 95% of eyes with PCV, and resulted in stable or improved VA 
one year after treatment. Unfortunately, one or more years after successful treatment 
with PDT, some eyes have a recurrence of the PCV lesions and, consequently, a 
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been successfully treated with PDT showed a recurrence of the polypoidal lesions during 
a follow-up of 24 months. These recurrent polypoidal lesions are often accompanied by 
an exudative change, which results in a poor visual prognosis in spite of retreatment 
using PDT.31-33 
     Several investigators have reported promising short-term results of PDT combined 
with bevacizumab for the treatment of PCV.34-38 Recently, Ruamviboonsuk and 
associates39 reported one-year results of 12 eyes with PCV that were treated with PDT 
combined with ranibizumab. To date, however, the efficacy and safety of this combined 
therapy has not been sufficiently evaluated.37 In addition, most reports have involved 
PCV that had no previous treatments.23, 35, 36, 39 In the clinical setting, physicians often 
need to treat eyes in which PCV has recurred after initial treatment with PDT or eyes with 
chronic PCV that is refractory to anti-VEGF agents,31-33 but, again, little information is 
available on the efficacy of combined therapy in such cases.34 Accordingly, the study 
described herein was designed to study the safety and efficacy of PDT combined with 
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PATIENTS AND METHODS 
 
For this case series, we studied retrospectively the medical records of 66 consecutive 
eyes (63 patients) with subfoveal PCV that were treated with PDT combined with 
intravitreal injections of ranibizumab (Lucentis; Novartis, Bülach, Switzerland) at Kyoto 
University Hospital between the beginning of May 2009 to the end of February 2011. 
Inclusion criteria of the study were (1) symptomatic subfoveal PCV, (2) presence of 
exudative or hemorrhagic features involving the macula, (3) VA of 0.7 or less on a 
Landolt chart before treatment, and (4) a minimum follow-up of 12 months after the initial 
treatment. The diagnosis of PCV was based on indocyanine green angiography, which 
shows a branching vascular network that terminates in polypoidal swelling. In the current 
study, all eyes showed a polypoidal lesion, a branching vascular network, or type 2 CNV 
beneath the foveal center. Eyes with other macular abnormalities (i.e., AMD, pathologic 
myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks and other 
secondary CNV) were excluded from the study. However, pseudophakic eyes were 
included, but eyes with a history of vitrectomy were excluded. 
     At the initial visit, each patient underwent a comprehensive ophthalmologic 
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determination of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy 
with a contact lens, spectral-domain optical coherence tomography (OCT) (Spectralis 
HRA+OCT, Heidelberg Engineering, Heidelberg, Germany), and fluorescein and 
indocyanine green angiography (HRA-2, Heidelberg Engineering). Patients who had a 
visual disturbance due to PCV were offered PDT combined with an intravitreal injection of 
0.5 mg ranibizumab. Injections of ranibizumab were performed in a sterile manner and 
prophylactic topical antibiotics were applied for 1 week after the injection. At 3-4 days 
after the intravitreal injection of ranibizumab, normal-fluence PDT was performed using a 
689 nm diode laser unit (Visulas PDT system 690S; Carl Zeiss, Dublin, California) after 
an injection of verteporfin (Visudyne; Novartis), according to PDT guidelines for AMD.40 
The greatest linear dimension chosen was based on fluorescein and indocyanine green 
angiograms, as previously described.28 All polypoidal lesions and the entire branching 
vascular network detected with indocyanine green angiography and type 2 CNV detected 
with fluorescein angiography were included. Serous pigment epithelial detachment was 
not included in the lesion area when the absence of underlying CNV was confirmed. 
     After the initial treatment, each patient was scheduled for an examination at 3 
months, at which time they again underwent a comprehensive ophthalmologic 
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polypoidal lesions and when an exudative change was seen on OCT, additional 
combination therapy was given. When residual polypoidal lesions were detected on 
indocyanine green angiography but no exudative change was seen on OCT, no 
additional treatment was given and the patient was reevaluated at the next visit. When 
only recurrent or residual exudative changes due to PCV were seen by OCT examination 
but neither polypoidal lesions nor type 2 CNV were seen on angiography, an additional 
injection of ranibizumab was given. After the additional injection of ranibizumab, the 
patient was scheduled to visit our clinic after one month, at which time they again 
underwent a comprehensive ophthalmologic examination. 
     In the current study, we studied 66 eyes with subfoveal PCV that were treated with 
PDT combined with intravitreal injections of ranibizumab. Of these 66 eyes, 29 had no 
history of treatment for PCV (treatment-naïve group). Ten eyes had been treated 
previously with only intravitreal injections of anti-VEGF agents, including ranibizumab, 
pegaptanib (Macugen; Pfizer, New York, New York), or bevacizumab (Avastin; 
Genentech, South San Francisco, California); these eyes had no history of PDT 
treatment (anti-VEGF group). Twenty-seven eyes had been treated previously with PDT 
for PCV (PDT group). Of the 27 eyes in the PDT group, 18 had also been treated 
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     All values are presented as mean ± standard deviation. For statistical analysis, 
best-corrected VA as measured with a Landolt chart was converted to a logarithm of the 
minimum angle of resolution (logMAR). VA was considered to be improved or 
deteriorated when the logMAR change was greater than 0.3. On OCT sections, foveal 
thickness was defined as the distance between the inner surface of the neurosensory 
retina and the retinal pigment epithelium beneath the fovea. In each group, VA or foveal 
thickness after the combined therapy was analyzed by one-way repeated measures 
analysis of variance with the Dunnett method. At each time point, the change in VA or in 
foveal thickness was analyzed using the least significant difference procedure. Software 
(StatMate III; ATMS, Tokyo, Japan) was used for the statistical analyses. A P value < .05 
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RESULTS 
 
In the study described herein, 66 eyes of 63 patients (44 men and 19 women), ranging in 
age from 57 to 85 years (72.1 ± 8.0 years), underwent PDT combined with intravitreal 
injections of ranibizumab for the treatment of PCV. All patients were Japanese, and all 
were of Asian ancestry. Of these 66 eyes, 29 had no history of treatment for PCV 
(treatment-naïve group). Ten eyes had previously been treated with only intravitreal 
injections of anti-VEGF agents (anti-VEGF group); the mean number of previous 
anti-VEGF treatment was 4.30 ± 2.83 (range: 1-9). Twenty-seven eyes had been treated 
previously for their PCV with PDT (PDT group); the mean number of previous PDT and 
anti-VEGF treatments was 1.63 ± 0.74 (range: 1-3) and 1.67 ± 1.03 (range: 0-4), 
respectively. In the study period over 12 months, the mean number of combined 
treatments was 1.38 ± 0.63 (range: 1-4). 
     In the treatment-naïve group, all eyes showed an exudative change due to the 
PCV; cystoid macula edema was seen in 9 eyes (31.0%), serous retinal detachment in 
27 (93.1%), and serosanguineous pigment epithelial detachment in 12 (41.4%). Initial 
combined therapy reduced substantially the exudative change. At three months, reduced 
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eyes, respectively. Of the 12 eyes with a serosanguineous pigment epithelial detachment, 
10 showed a reduction of its size and 5 showed complete resolution at three months. Of 
24 eyes examined at three months with indocyanine green angiography, the polypoidal 
lesion was reduced in size in all eyes and had disappeared completely in 19 eyes 
(79.1%) (Figures 1 and 2). However, a branching vascular network remained in all eyes. 
     Figure 3 shows the change in VA and in foveal thickness after treatment of the 
treatment-naïve group. Combined therapy reduced substantially the exudative change 
immediately after initiation of treatment. The foveal thickness was reduced significantly 
from 390.3 ± 143.2 µm before treatment to 252.9 ± 104.3 µm (P < .01) at three months, 
and to 227.4 ± 50.3 µm (P < .01) at 12 months. The mean VA before treatment (0.47 ± 
0.37) also improved significantly, being 0.32 ± 0.30 (P < .01) at three months. The 
improvement of VA was maintained until 12 months (0.29 ± 0.29, P < .01). At 12 months, 
significant improvement of VA was seen in 10 eyes (34.5%) and deterioration of VA was 
seen in one eye (3.5%) (Figure 4). Over this 12-month period, additional combined 
therapy to residual polypoidal lesions with an exudative change was performed in 9 eyes 
(31.0%). If only an exudative change remained, additional ranibizumab injections were 
given (7 eyes; 24.1%). In the treatment-naïve group, although two eyes showed 
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hemorrhage was absorbed spontaneously with no decrease in VA (Figure 5). During this 
12-month period, no other serious adverse event was seen in the treatment-naïve group. 
     In the anti-VEGF group, combined therapy reduced substantially the exudative 
change. The mean foveal thickness was reduced significantly from 434.8 ± 243.2 µm 
before treatment to 276.1 ± 148.9 µm (P < .05) at three months, and to 311.4 ± 166.7 µm 
(P < .05) at 12 months. The mean VA was improved from 0.51 ± 0.36 before treatment to 
0.39 ± 0.37 at three months and to 0.40 ± 0.46 at 12 months, although this improvement 
was not statistically significant. At 12 months, significant improvement of VA was seen in 
three eyes (30.0%) while significant deterioration was seen in one (10.0%). During the 
first 12 months, additional combined therapy was performed in four eyes (40.0%) and 
additional ranibizumab injections were given in one eye (10.0%). During 12 months, no 
serious adverse event was seen in any eye of the anti-VEGF group. 
     In the PDT group, combined therapy reduced substantially the exudative change. 
The mean foveal thickness was reduced significantly from 399.3 ± 211.8 µm before 
treatment to 266.0 ± 95.2 µm (P < .01) at three months, and to 318.0 ± 140.6 µm (P < .01) 
at 12 months. With treatment, however, the mean VA did not improve throughout the 
follow-up period. The mean VA (0.61 ± 0.45 before treatment) remained 0.61 ± 0.46 at 
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months, significant improvement of VA was seen in only three eyes (11.1%) while 
significant deterioration was seen in five (18.5%). During 12 months, additional combined 
therapy was performed in eight eyes (29.6%) and additional ranibizumab injections were 
given to in two eyes (7.4%). In this PDT group, three eyes showed extensive subretinal 
hemorrhage after treatment. Of these, two developed vitreous hemorrhage and 
underwent pars plana vitrectomy. 
     Table 2 shows the change in VA and foveal thickness from pretreatment values in 
each group. No difference was seen in the change of foveal thickness among the three 
groups. In addition, no significant difference was seen in the change of VA between the 
treatment-naïve group and the anti-VEGF group. However, change of VA in the PDT 
group was significantly worse than that of the treatment-naïve group at three months and 
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DISCUSSION 
 
Several investigators have reported the effects of anti-VEGF agents for the treatment of 
exudative PCV.13-18, 21-24 Cheng and associates24 recently reported one-year results of 
intravitreal injections of bevacizumab for PCV. With a mean of 3.3 injections per affected 
eye over 12 months, mean VA (logMAR) improved from 0.79 ± 0.42 to 0.67 ± 0.51, 
although complete resolution of the polypoidal lesions was confirmed in only 16.1% of the 
eyes. With the use of another anti-VEGF agent, Kokame and associates22 showed that 
monthly injections of ranibizumab successfully reduced the exudative changes of PCV. 
However, even with monthly injections, reduction of the polypoidal lesion was achieved in 
only 33% of eyes, and the branching vascular network remained in all eyes. While 
anti-VEGF agents can reduce the exudative change due to PCV, often resulting in VA 
recovery, their effect on the reduction of the vascular lesions of PCV appears limited.13-24 
     In contrast, a number of studies have shown encouraging results of PDT for the 
vascular lesions of PCV,26-30 and complete regression of the polypoidal lesions is usually 
achieved with a small number of PDT sessions.26-30 In a report by Chan and associates,27 
PDT resulted in complete regression of polypoidal lesion in 95% of eyes with PCV. 


































































Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 13 
than in those with AMD; Gomi and associates29 have shown that the median change in 
VA from baseline to 1 year was -7.0 letters in AMD and +8.0 letters in PCV. However, 
even if all of the polypoidal lesions regress with PDT, its effect on the branching vascular 
network remains limited,28, 29 and the remaining branching vascular network may be 
involved in the recurrence of polypoidal lesions one or even more years after successful 
treatment with PDT.31-33, 41 
     In the combination therapy, anti-VEGF agents, which rapidly reduce the exudative 
change,13-18, 21-24 are expected to contribute to visual recovery in cooperation with 
regression of the polypoidal lesions induced by PDT.26-30 In addition, because increased 
expression of VEGF shortly after PDT has been reported,42 it seems logical to inject an 
anti-VEGF agent before PDT treatment.23, 34-36, 39 Recently, several investigators reported 
promising one-year results of PDT combined with bevacizumab for the treatment of PCV 
(Table 3).23, 35, 36, 38 Using PDT in combination with bevacizumab for PCV, Sato and 
associates35 reported that the mean improvement in VA was 2.69 lines, and that VA 
improved by 3 lines or more in 51.7% of eyes, and, using a similar combination of 
ranibizumab and PDT for 12 eyes with PCV, Ruamviboonsuk and associates39 achieved 
a gain in VA of 15 letters or more in 58.3 % of eyes at 12 months. 
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the polypoidal lesions disappeared completely in 79.1% of eyes, with a substantial 
reduction in exudative change. The mean change in VA was -0.16 ± 0.27 at 3 months and 
was -0.18 ± 0.34 at 12 months. Otani and associates28 previously reported one-year 
results of PDT alone on subfoveal PCV, with inclusion criteria quite similar to those of the 
current study (Table 3). In that report,28 the mean number of treatments was no different 
from that of the present study. However, changes in VA at 3 months (-0.05 ± 0.17) and at 
12 months (-0.11± 0.30) were less than in the current study, although the difference was 
not statistically significant. Our findings are consistent with those recently reported by 
Gomi and associates,36 who found that PDT combined with bevacizumab for the 
treatment of PCV yielded better visual recovery at one year than did PDT alone.36 Thus, 
for the treatment of PCV, PDT in combination with anti-VEGF agents seems to have a 
good effect on short-term visual recovery.34-36, 38, 39 
     Recently, a randomized prospective study (EVEREST study) has shown the 
6-month efficacy of PDT in combination with ranibizumab for PCV (Lai TY, et al. IOVS 
2010;51:ARVO E-Abstract 2228). In that study, complete regression of polypoidal lesions 
was achieved at 6 months in 77.8% after combination therapy, in 71.4% after PDT alone, 
and in 28.6% after intravitreal injections of ranibizumab. The mean change in VA at 6 
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groups, respectively; PCV eyes treated with PDT combined with ranibizumab achieved 
the highest gains of VA at 6 months. Our results in the treatment-naïve group are quite 
similar to those of the combination group in the EVEREST study. However, because the 
current study is retrospective, it is difficult to compare strictly our results with those of the 
EVEREST study. 
     In the study described herein, PCV that recurred after previous PDT did, indeed, 
show a reduction of exudative change, but this did not result in further visual recovery, an 
observation similarly reported by Romano and associates,34 who observed that in eyes 
with PCV that were refractory to treatment by PDT alone, PDT combined with 
bevacizumab resulted in morphologic stabilization of the PCV lesions, but not in visual 
recovery.34 The reason for the poor change in VA seen in the PDT group after the 
combined therapy is unclear, although damage of the choriocapillaris or retinal pigment 
epithelium due to previous PDT might be involved. Rather, recent reports have shown the 
association of some genetic factors to the response to PDT and to subsequent visual 
prognosis in eyes with PCV.43, 44 Originally, PDT group might consist of the eyes that 
have genetically poor VA prognosis. 
     To date, limited information is available on combined therapy for PCV that is 
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can be expected when PDT is combined with ranibizumab, even in eyes with PCV that 
were previously treated with anti-VEGF agents. Because the effect of anti-VEGF therapy 
on polypoidal lesions is limited,13-18, 21-24 combined therapy may well be a treatment 
option when recurrent or persistent exudative change is seen after anti-VEGF 
treatments. 
     For treatment of PCV, one of the most vision-threatening complications of PDT is 
extensive postoperative hemorrhage.45, 46 In a previous paper on PCV treated with PDT, 
Hirami and associates45 reported that postoperative subretinal hemorrhage was seen in 
28 (30.8%) of 91 eyes, and that bleeding resulted in a vitreous hemorrhage in 6 eyes. 
Recent reports by Gomi and associates36 and by Sato and associates35 suggested a 
lower incidence of subretinal hemorrhage when the PDT was combined with 
bevacizumab. In the current study, two eyes in the treatment-naïve group had an 
extensive subretinal hemorrhage (larger than 4 disc areas) after such combined therapy, 
although the hemorrhage was absorbed spontaneously with no decrease in VA. In 
addition, three eyes in the PDT group had an extensive subretinal hemorrhage after 
treatment, and this resulted in vitreous hemorrhage in two eyes, so it is uncertain whether 
or not combined therapy actually reduces the posttreatment hemorrhagic complications. 
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physicians need to keep in mind the risk to their patients of these complications. 
     Major limitations of the current study are its retrospective nature, its small sample 
size, and its lack of control individuals. Furthermore, we used a Landolt chart, which is 
based on an uneven spatial gradient scale, for the measurement of VA. However, despite 
these shortcomings, our findings suggest that PDT combined with intravitreal injections 
of ranibizumab results in rapid regression of the polypoidal lesions and exudative 
changes, and often results in improvement of VA in eyes with treatment-naïve PCV. 
Patients with PCV treated with PDT combined with ranibizumab do have a risk of 
posttreatment hemorrhagic complications. However, because our findings are based on 
an observation period of only 12 months, it remains unclear whether or not PDT in 
combination with ranibizumab reduces the recurrence rate of PCV. Because the 
long-term efficacy of PDT alone is not as promising as was thought initially, prospective 
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Figure captions 
 
Figure 1. Treatment-naïve polypoidal choroidal vasculopathy. (Top left) Fundus 
photograph shows multiple serosanguineous pigment epithelial detachments with 
surrounding subretinal hemorrhage. Visual acuity of the left eye was 0.03. (Top middle) 
Fluorescein angiography reveals occult choroidal neovascularization (CNV). (Top right) 
Indocyanine green angiography (IA) shows polypoidal lesions that appear similar to a 
cluster of grapes (yellow arrow). (2nd row) A section of optical coherence tomography 
along white arrow shown in IA picture reveals a protrusion of retinal pigment epithelium 
due to polypoidal lesions (yellow arrow). Left eye was treated with photodynamic therapy 
combined with an intravitreal injection of ranibizumab. (3rd row, left) Three months after 
the initial treatment, subretinal hemorrhage has been absorbed and visual acuity of the 
left eye has improved to 0.3. (3rd row, middle) Fluorescein angiography shows atrophy of 
the retinal pigment epithelium. (3rd row, right) IA shows no polypoidal lesions. (Bottom) A 
section of optical coherence tomography along white arrow shown in IA reveals minimal 
exudative change with smaller pigment epithelial detachments. Visual acuity at 12 
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Figure 2. Treatment-naïve polypoidal choroidal vasculopathy. (Top left) Fundus 
photograph at the initial visit shows subfoveal exudates and hemorrhage. Visual acuity of 
the left eye was 0.4. (Top middle) Fluorescein angiography (FA) reveals subfoveal 
classic choroidal neovascularization. (Top right) Indocyanine green angiography shows a 
branching vascular network that terminates in polypoidal lesions (arrows). (2nd row) A 
section of optical coherence tomography along white arrow shown on FA reveals a 
protrusion of retinal pigment epithelium due to polypoidal lesions (arrow) and overlying 
fibrin exudate. Left eye was treated with photodynamic therapy combined with an 
intravitreal injection of ranibizumab. (3rd row, left) Three months after treatment, the 
subretinal hemorrhage and exudates have been absorbed and visual acuity of the left 
eye has improved to 0.8. (3rd row, middle) FA shows no classic choroidal 
neovascularization. (3rd row, right) Indocyanine green angiography shows no polypoidal 
lesions. (Bottom) A section of optical coherence tomography along white arrow shown on 
FA shows only reduced protrusion of the retinal pigment epithelium. Visual acuity at 12 
months was 0.9. 
 
Figure 3. Mean foveal thickness (top) and mean visual acuity in logMAR fashion (bottom) 
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combined with intravitreal injections of ranibizumab. *P < .01, †P < .05, compared with 
pretreatment values. VEGF = vascular endothelial growth factor. 
 
Figure 4. Improvement and deterioration of visual acuity at 12 months after 
photodynamic therapy (PDT) combined with an intravitreal injection of ranibizumab for 
the treatment of polypoidal choroidal vasculopathy. Visual acuity was considered to be 
improved or deteriorated when the change in logMAR units was greater than 0.3. VEGF 
= vascular endothelial growth factor. 
 
Figure 5. Extensive subretinal hemorrhage seen in polypoidal choroidal vasculopathy 
after photodynamic therapy combined with intravitreal injections of ranibizumab. (Top 
left) Treatment-naïve polypoidal choroidal vasculopathy before treatment (0.5 OD). (Top 
middle) One month after combined therapy, the subretinal hemorrhage has increased 
(0.6 OD). (Top right) Subretinal hemorrhage has been absorbed with no treatment.  
Visual acuity at 12 months was 0.7 OD. (Middle left) Treatment-naïve polypoidal 
choroidal vasculopathy before treatment (0.3 OD). (Center) One month after the 
combined therapy, subretinal hemorrhage has increased (0.3 OD). (Middle right) 
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was 0.5 OS. (Bottom left) Polypoidal choroidal vasculopathy recurred three years after 
the initial photodynamic therapy (0.3 OD). (Bottom middle) Six weeks after combined 
therapy, extensive subretinal hemorrhage is seen (0.01 OD); this eye subsequently 
developed a vitreous hemorrhage. (Bottom right) After pars plana vitrectomy, a large 
disciform scar is seen (0.02 OS at 12 months). 
 
Figure 6. Polypoidal choroidal vasculopathy recurred after two sessions of photodynamic 
therapy (PDT). (Top left) Fundus photograph shows multiple serosanguineous pigment 
epithelial detachments with surrounding subretinal hemorrhage. Visual acuity of the left 
eye was 0.05. (Top middle) Fluorescein angiography reveals occult choroidal 
neovascularization. (Top right) Indocyanine green angiography (IA) shows a branching 
vascular network that terminates in polypoidal lesions (yellow arrow). (2nd row) A section 
of optical coherence tomography along white arrow shown on IA reveals protrusions of 
the retinal pigment epithelium due to polypoidal lesions. The left eye was treated with 
photodynamic therapy combined with an intravitreal injection of ranibizumab. (3rd row, 
left) Three months after treatment, subretinal hemorrhage and exudates have been 
absorbed. Visual acuity of the left eye was 0.1. (3rd row, middle) FA shows no choroidal 
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optical coherence tomography along white arrow pictured on IA shows minimal 
protrusion of the retinal pigment epithelium. Visual acuity at 12 months remained at 0.1 in 
the left eye. 
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Number of eyes 66 29 10 27 
Age (years) 72.1 ± 8.0 70.7 ± 9.9 72.3 ± 5.5 73.5 ± 6.3 
Gender (women/men) 20/46 11/18 2/8 7/20 
Number of previous anti-VEGF treatments - - 4.3 ± 2.8 1.7 ± 1.0 
Number of previous PDT treatments - - - 1.6 ± 0.7 
Initial visual acuity (logMAR) 0.53 ± 0.40 0.47 ± 0.37 0.51 ± 0.36 0.61 ± 0.45 
Initial total foveal thickness (µm) 401.0 ± 188.9 390.3 ± 143.2 434.8 ± 243.2 399.3 ± 211.8 
Cystoid macular edema 20 9 3 6 
Serous retinal detachment 57 27 8 22 
Subretinal hemorrhage 42 22 6 14 
Pigment epithelial detachment 30 12 7 11 
Greatest linear dimension 4530 ± 1339 4147 ± 1171 4968 ± 1704 4780 ± 1301 
Additional anti-VEGF therapy 10 7 1 2 
       Number of additional anti-VEGF treatments    
                    (range) 
0.39 ± 1.20 
(1-7) 
0.69 ± 1.65 
(1-7) 
0.30 ± 0.95 
(1-3) 
0.11 ± 0.42 
(1-2) 
Additional combined therapy 21 9 4 8 
       Number of additional combined therapy 
                (range) 
0.38 ± 0.63 
(1-3) 
0.31 ± 0.47 
(1) 
0.50 ± 0.71 
(1-2) 
0.41 ± 0.75 
(1-3) 
VEGF = vascular endothelial growth factor; PDT = photodynamic therapy; logMAR = logarithm of the minimum angle of resolution. 
Treatment-naïve group consisted of eyes with no previous treatment for polypoidal choroidal vasculopathy (PCV). Anti-VEGF group 
consisted of eyes that were treated previously with only intravitreal injections of anti-VEGF agents for PCV with no history of PDT 
treatment. PDT group consisted of eyes previously treated with PDT for PCV. 
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TABLE 2. Changes in Visual Acuity and Foveal Thickness after Photodynamic Therapy Combined with Intravitreal Injections of 
Ranibizumab for Polypoidal Choroidal Vasculopathy 
 2 weeks   3 months 6 months 9 months 12 months 
Change in visual acuity (logMAR)      
         Total group -0.01 ± 0.14 -0.09 ± 0.27 -0.07 ± 0.30 -0.06 ± 0.35 -0.07 ± 0.35 
         Treatment-naïve group -0.02 ± 0.14 -0.16 ± 0.27 -0.13 ± 0.27 -0.16 ± 0.35 -0.18 ± 0.34 
         Anti-VEGF group -0.02 ± 0.14 -0.12 ± 0.20 -0.16 ± 0.26 0.10 ± 0.34 -0.11 ± 0.34 
         PDT group 0.01 ± 0.14 0.00 ± 0.26* 0.03 ± 0.33* 0.05 ± 0.33* 0.07 ± 0.33* 
Change in foveal thickness (µm)     - 
         Total group - -139.0 ± 148.3 -141.7 ± 162.1 - -125.9 ± 189.5 
         Treatment-naïve group - -137.4 ± 150.4 -154.1 ± 141.2 - -171.3 ± 150.2 
         Anti-VEGF group - -158.7 ± 154.2 -139.3 ± 154.5 - -123.4 ± 262.4 
         PDT group - -133.4 ± 149.2 -130.1 ± 187.4 - -81.4 ± 190.8 
LogMAR = logarithm of the minimum angle of resolution; VEGF = vascular endothelial growth factor; PDT = photodynamic 
therapy. 
Treatment-naïve group consisted of eyes with no previous treatment for polypoidal choroidal vasculopathy (PCV). Anti-VEGF 
group consisted of eyes that were treated previously with only intravitreal injections of anti-VEGF agents for PCV with no history 
of PDT treatment. PDT group consisted of eyes previously treated with PDT for PCV. 
*P < .05, compared with treatment-naïve group. 
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Change in VA 
at 3 month 
 
Change in VA 
at 12 months 
Improvement of 
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at 12 months 
Deterioration of 
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29 0.47 ± 0.37 -0.16 ± 0.27 -0.18 ± 0.34 34.5% 3.4% 1.31± 0.47 
Otani and associates
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12 0.725 10.8 letters 
in ETDRS  
12.3 letters 
in ETDRS 





9 0.81  -0.18 0% - 1.67 
PDT = photodynamic therapy; VA = visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study. 
Visual acuity is presented as logarithm of the minimum angle of resolution, if not otherwise indicated. 
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Table of Contents Statement 
 
In eyes with polypoidal choroidal vasculopathy, photodynamic therapy combined with 
intravitreal injections of ranibizumab substantially diminished the polypoidal lesion and 
reduced the exudative change. This combined therapy led to significant visual recovery 
in eyes with polypoidal choroidal vasculopathy that were treatment-naive, but not in eyes 
with polypoidal choroidal vasculopathy that had recurred after previous photodynamic 
therapy. Photodynamic therapy in combination with ranibizumab does, however, still 
have a risk of the postoperative hemorrhagic complications.  
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